当前位置:首页 - 行情中心 - 川宁生物(301301) - 财务分析 - 现金流量表

川宁生物

(301301)

  

流通市值:49.97亿  总市值:180.15亿
流通股本:6.19亿   总股本:22.32亿

现金流量表

报告期2026-09-302026-06-302026-03-312025-12-31
公司类型通用通用通用通用
一、经营活动产生的现金流量:
  销售商品、提供劳务收到的现金2,525,828,665.231,816,019,158.89577,902,889.733,372,852,789.69
  收到的税费返还65,424,252.4656,928,758.181,610,619.57,752,108.42
  收到其他与经营活动有关的现金41,807,898.6633,297,408.2418,380,743.11106,323,178.81
  经营活动现金流入小计2,633,060,816.351,906,245,325.31597,894,252.343,486,928,076.92
  购买商品、接受劳务支付的现金1,105,364,578.55636,200,658.98155,293,761.151,834,727,762.28
  支付给职工以及为职工支付的现金388,180,675.75279,961,228.87168,207,053.62497,582,852.28
  支付的各项税费300,099,323.21203,415,721.2885,067,170.75524,858,829.31
  支付其他与经营活动有关的现金16,207,941.9911,314,881.426,645,330.8780,699,154.72
  经营活动现金流出小计1,809,852,519.51,130,892,490.55415,213,316.392,937,868,598.59
  经营活动产生的现金流量净额823,208,296.85775,352,834.76182,680,935.95549,059,478.33
二、投资活动产生的现金流量:
  收回投资收到的现金1,011,116,845.43770,801,434.09550,606,794.642,791,038,607.77
  取得投资收益收到的现金-99,040-0
  处置固定资产、无形资产和其他长期资产收回的现金净额54,785.89--154.87
  投资活动现金流入小计1,011,171,631.32770,900,474.09550,606,794.642,791,038,762.64
  购建固定资产、无形资产和其他长期资产支付的现金53,307,385.4729,894,314.4317,049,007.7197,211,603.8
  投资支付的现金1,268,076,923993,000,000603,000,0002,925,759,277.78
  支付其他与投资活动有关的现金288,388.04-6,830-
  投资活动现金流出小计1,321,672,696.511,022,894,314.43620,055,837.713,022,970,881.58
  投资活动产生的现金流量净额-310,501,065.19-251,993,840.34-69,449,043.07-231,932,118.94
三、筹资活动产生的现金流量:
  吸收投资收到的现金8,787,398.48,787,398.4-20,135,520
  其中:子公司吸收少数股东投资收到的现金---7,200,000
  取得借款收到的现金606,804,568.94399,981,132.08200,000,000747,990,436.81
  筹资活动现金流入小计615,591,967.34408,768,530.48200,000,000768,125,956.81
  偿还债务支付的现金688,000,000358,000,000346,000,000817,333,333
  分配股利、利润或偿付利息支付的现金399,245,307.27395,775,999.25,937,913.05622,104,954.13
  支付其他与筹资活动有关的现金34,456,944.832,456,944.826,879,329.62,603,515.2
  筹资活动现金流出小计1,121,702,252.07786,232,944378,817,242.651,442,041,802.33
  筹资活动产生的现金流量净额-506,110,284.73-377,464,413.52-178,817,242.65-673,915,845.52
四、汇率变动对现金及现金等价物的影响-5,670,665.14-4,577,612.08-5,105,726.252,670,112.45
五、现金及现金等价物净增加额926,281.79141,316,968.82-70,691,076.02-354,118,373.68
  加:期初现金及现金等价物余额734,213,300.93734,213,300.93734,213,300.931,088,331,674.61
  期末现金及现金等价物余额735,139,582.72875,530,269.75663,522,224.91734,213,300.93
补充资料:
  净利润-274,081,202.28-768,346,157.39
  资产减值准备-9,788,239.55-27,737,334.93
  固定资产和投资性房地产折旧-283,371,510.19-552,923,990.02
  其中:固定资产折旧、油气资产折耗、生产性生物资产折旧-283,371,510.19-552,923,990.02
  无形资产摊销-10,069,815.15-19,627,677.52
  长期待摊费用摊销-439,126.5-878,253.01
  处置固定资产、无形资产和其他长期资产的损失----345,957.83
  固定资产报废损失-715,672.38-1,390,522.65
  公允价值变动损失-217,381.95-1,483,217.89
  财务费用-22,900,274.53-40,474,674.98
  投资损失-1,401,695.02-2,071,203.43
  递延所得税-1,600,120.64--922,003.27
  其中:递延所得税资产减少-1,600,120.64--922,003.27
  存货的减少-89,944,221.9--182,286,435.89
  经营性应收项目的减少-75,073,317.93--527,477,968.93
  经营性应付项目的增加--2,718,810.68--162,487,727.15
  其他----7,297,177.5
  不涉及现金收支的投资和筹资活动金额其他项目---10,162,374.09
  现金的期末余额-875,530,269.75-734,213,300.93
  减:现金的期初余额-734,213,300.93-1,088,331,674.61
  现金及现金等价物的净增加额-141,316,968.82--354,118,373.68
公告日期2026-10-232026-08-252026-04-232026-03-31
审计意见(境内)标准无保留意见
TOP↑